1) Fujiwara K, Owaki HH, Fujimoto M, et al:A long-term follow-up study of cervical lesions in rheumatoid arthritis. J Spinal Disord 13:519-526, 2000
2) Kaito T, Hosono N, Ohshima S, et al:Effect of biological agents on cervical spine lesions in rheumatoid arthritis. Spine 37:1742-1746, 2012
3) Kaito T, Ohshima S, Fujiwara H, et al:Predictors for the progression of cervical lesion in rheumatoid arthritis under the treatment of biological agents. Spine 38:2258-2263, 2013
4) Lipsky PE, van der Heijde DM, St Clair EW, et al:Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594-1602, 2000
5) Maini RN, Breedveld FC, Kalden JR, et al:Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50:1051-1064, 2004
6) Oda T, Fujiwara K, Yonenobu K, et al:Natural course of cervical spine lesions in rheumatoid arthritis. Spine 20:1128-1135, 1995
7) Smolen JS, Landewe R, Breedveld FC, et al:EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2013.Ann Rheum Dis 73:492-509, 2014
8) Stein BE, Hassanzadeh H, Jain A, et al:Changing trends in cervical spine fusions in patients with rheumatoid arthritis. Spine 39:1178-1182, 2014
9) Yamanaka H, Sugiyama N, Inoue E, et al:Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol 24:33-40, 2014
10) Yurube T, Sumi M, Nishida K, et al:Progression of cervical spine instabilities in rheumatoid arthritis. Spine 36:647-653, 2011